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SUMMARY 
 
Background 
Systemic sclerosis (SSc) is an autoimmune disease associated with significant mortality 
and morbidity.  Cardiovascular causes are the single largest contributor to premature 
death.  To date, much of the focus on managing the care of SSc patients has 
concentrated on traditional risk factors related to fibrotic and microvascular 
dysfunction. There is, however, evidence of a strong cardiovascular component to the 
disease and points to macrovascular dysfunction as being a key contributor to the 
premature mortality associated with SSc. This thesis reports on the conduct of a multi-
centre, randomised, placebo-controlled clinical trial (the SSTEP Study). The aim of the 
study was to assess whether oral Iloprost was more effective than placebo in reducing 
cardiovascular events and disease progression in SSc. 
 
Methods 
Two hundred and sixteen patients with systemic sclerosis were recruited, between 
February 2002 and February 2005, at nine centres in the UK and Ireland. After one 
month placebo run-in, participants were randomised to either oral Iloprost (50-200mcg 
daily) or matched placebo. Baseline demographics, disease characteristics and organ 
screening data were collected, and participants were reviewed annually for endpoint 
measurements; CV events, SSc disease progression and mortality, with regular safety 
reviews between these annual visits. Participants were followed up for a period of 4 to 7 
years. 
 
 
xxiii 
 
Results 
Data analysis of the combination of the two measures (survival free from death or a 
cardiovascular event) demonstrated a trend towards favouring Iloprost over placebo but 
the difference was not statistically significant (Logrank test: Chi square=0.75, p=0.39). 
When time to a confirmed cardiovascular endpoint alone was examined there was a 
suggestion of a benefit from Iloprost, but the difference was again not statistically 
significant (Logrank test, Chi square =0.82, p=0.37).  There was no statistically 
significant change in the rate at which organ screening endpoints occurred throughout 
follow-up, and for each endpoint there was no statistically significant difference 
between results in patients randomised to Iloprost compared to those randomised to 
placebo. Withdrawal from the treatment to which the patient was randomised was 
frequent with 97 (45%) of the total participants discontinuing study medication.   ‘On 
treatment’ analysis, undertaken using the endpoint of death or confirmed cardiovascular 
endpoint, just failed to show statistical significance at the 5% level (p=0.054). 
 
Conclusion 
The results of the SSTEP study showed that there was a trend towards favouring oral 
Iloprost over placebo in systemic sclerosis, though there was no statistically significant 
evidence to recommend its use to prevent disease progression. The high rate of 
withdrawal from both Iloprost and placebo hindered the possibility of demonstrating 
that Iloprost was effective in this study.  It cannot be concluded that it is a useful 
therapy that may prevent premature mortality or progression to cardiovascular disease 
in this patient group.   
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